Stem Cell Therapy Global Market Report 2023 – By Type (Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy), By Cell Source (Adult Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells), By Application (Musculoskeletal Disorders, Wounds and Injuries, Cancer, Autoimmune Disorders, Other Applications), By EndUser (Hospitals, Clinics) – Market Size, Trends, And Global Forecast 2023-2032

Cell culture is a process for developing substrates for the safe production of viral vaccines. 3D cell culture is an in vitro technique wherein the cells can grow in an artificially created environment. The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The main types of 3D cell culture technologies are scaffold-based, scaffold-free, and 3D bioreactors. The 3D bioreactors are small plastic cylinder chambers designed specifically for growing cells in three dimensions. The various scaffold-based technologies include hydrogels, polymeric scaffolds, micropatterned surface microplates and the different scaffold-free technologies are hanging drop microplates, spheroid microplates, microfluidic 3d cell culture, magnetic levitation and 3D bioprinting. The technologies are applied for cancer research, stem cell research, drug discovery, and regenerative medicine that are used by research laboratories and institutes, biotechnology and pharmaceutical companies, hospitals and diagnostic centers, and other end users. The global 3D cell culture technologies market is segmented – 1) By Type: Scaffold-based, Scaffold-free, 3D Bioreactors 2) By End Users: Research Laboratories and Institutes, Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostic Centers, Other End Users 3) By Scaffold-based: Hydrogels, Polymeric scaffolds, Micropatterned Surface Microplates 4) By Scaffold-free: Hanging Drop Microplates, Spheroid Microplates, Microfluidic 3D Cell Culture, Magnetic Levitations & 3D Bioprinting 5) By Application: Cancer Research, Stem Cell Research, Drug Discovery, Regenerative Medicine The global 3d cell culture technologies market size grew from $2.39 billion in 2022 to $2.83 billion in 2023 at a compound annual growth rate (CAGR) of 18.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the 3d cell culture technologies market is expected to grow from $5.65 billion in 2027 at a CAGR of 18.9%. The increasing requirement for organ transplantation is driving the 3D Cell Culture Technologies Market. 3D cell culture helps in forming a three-dimensional structure which further helps in mimicking the tissue or organ and therefore helps in organ transplantation. 3D cell structures are capable of tissue and organ regeneration as well as providing the provision for drug toxicology screening. For instance, according to the Organ Procurement and Transplantation network, an American non-profit organization administering the organ transplantation in the US, 41,354 organ transplantations were performed in the United States in 2021 which was an increase of 5.9% as compared to 2020 and the number exceeded 40,000 mark for the first time ever. Major players in the 3D cell culture technologies market are Becton Dickinson, Corning Incorporation, Eppendorf, GE Healthcare, Merck KGaA, Thermo Fisher Scientific, Lonza, HiMedia Laboratories, Agilent Technologies, PromoCell GmbH, CellGenix GmbH, InvivoGen, Greiner Bio-One, Irvine Scientific, Cell Culture Company (CCC) LLC., Sera Care Life Sciences Incorporation, American Type Culture Collection, Miltenyi Biotec, AITbiotech, ESSEN, Sigma-Aldrich, Bel-Art, MilliporeSigma, Cellgenix, Sumitomo Bakelite, EMD Millipore, AffymetrixInc., VWR International, LLC., WHEATON IndustriesInc., and Sartorius A. The possibility of contaminating the cells is restricting the 3D Cell Culture technologies market. Contamination of the cell culture refers to the presence of bacteria, moulds, yeasts, viruses, and mycoplasma that can adversely affect the cell culture. Contamination usually occurs when the cells are mishandled or due to the lack of adequate care, as a result the process of regeneration may get affected. According to a study conducted by Yale and Tuff's university, it was found that 3D cultures are more complex than 2D cell cultures and they require a more controlled cellular environment in order to mimic structures for tissue or organ transplants. Therefore, probability of cell culture contamination is relatively higher in 3D cell cultures. Implementing the latest technology is the latest trend in the 3D Cell culture market. For example, various companies have adopted one such advancement in the market for 3D cell culture, this is the use of the vivo/vitro environment. Cell expansion and interactions under 2D are not appropriate in vitro models but when compared with 3D cell culture technique, it offers a better cell culture environment. The Vitro environment enables researchers or doctors to conduct the procedure in a controlled environment outside the organism. This procedure is gaining importance as it plays a vital role in monitoring the health of patients. FDA approved Biotek's 3D cell expansion system to be used as a medical device. It also approved Biotek's Polycaprolactone (PCL) which is a biodegradable polyester material that is used in many FDA-approved implants and drug delivery devices. FDA regulates the cell culture technologies under title 21, sec 864.2240. FDA states that cell and tissue culture technologies should be labelled or mentioned as sterile, or else they would be removed from the good manufacturing practice of the quality system. Each technology unit should maintain procedures to receive, review, and evaluate complaints. These procedures should also include consistent documentation of the receipts. In May 2021, CELLINK Group, a USA-based start-up that designs and supplies technologies and services to enhance biology research, has acquired Visikol Corporation for $7.5 million. With this acquisition, CELLINK made an entrance into the contract research market. Visikol Corp., an American contract research services company that provides pharma and biotech industries with leading services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology. North America was the largest region in the 3D cell culture technologies market in 2022. Western Europe was the second largest region in the 3D cell culture technologies market share. The regions covered in the global 3D cell culture technologies market report analysis are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the 3D cell culture technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The 3D cell culture technologies market consists of sales of 3D cell culture technologies such as microfluidics, hydrogels scaffolds, scaffold-free 3D cell culture techniques, spheroids, cube, spherical droplet, stacked plate, magnetic bead, organ-on-chips and other technologies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The 3D cell culture technologies market research report is one of a series of new reports from The Business Research Company that provides 3D cell culture technologies market statistics, including 3D cell culture technologies industry global market size, regional shares, competitors with a 3D cell culture technologies market share, detailed 3D cell culture technologies market segments, market trends and opportunities, and any further data you may need to thrive in the 3D cell culture technologies industry. This 3D cell culture technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell culture consumables and equipment are designed to aid scientists in growing new cells in the culture media for drug development, tissue culture, engineering, gene therapy, vaccine production, and toxicity testing. The main products in cell culture consumables and equipment are consumables and instruments. The cell culture instruments involve the various instruments that are required for cell culture in the cell culture laboratory. The various instruments used in cell culture are cell culture vessels, bioreactors, biosafety cabinets, carbon dioxide incubators, and centrifuge and consumables are media, sera, and reagents. The applications involved are vaccination, toxicity testing, cancer research, drug screening and development, recombinant products, stem cell technology, regenerative medicine, and others that are used by end-users such as industrial, biotechnology, agriculture, and others. The global is segmented - 1) By Product: Consumables, Instruments 2) By End User: Industrial, Biotechnology, Agriculture, Other End Users 3) By Application: Vaccination, Toxicity testing, Cancer Research, Drug Screening and Development, Recombinant Products, Stem cell technology, Regenerative Medicine, Other End Users 4) By Consumables: Media, Sera, Reagents 5) By Instruments: Cell Culture Vessels, Bioreactors, Biosafety Cabinets, Carbon Dioxide Incubators, Centrifuges The global cell culture consumables and equipment market grew from $10.99 billion in 2022 to $12.12 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the cell culture consumables and equipment is expected to grow from $17.98 billion in 2027 at a CAGR of 10.4%. An increase in the prevalence of chronic diseases is driving the growth of the cell culture consumables and equipment market. Chronic diseases such as cancer, diabetes, heart diseases, obesity, and hypertension are growing rapidly. A few chronic diseases are caused due to loss or damage of certain types of cells. Such diseases can be cured by replacing the destroyed cells with new ones that are produced by pluripotent stem cells, using cell culture consumables and equipment. So, with the rising incidence of chronic diseases, there is an increased need for such equipment that can produce new cells outside the natural environment, thus driving the growth of this market. For example, according to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020. Major players in the cell culture consumables and equipment market are Becton Dickinson, Corning Incorporation, Eppendorf, GE Healthcare, Merck KGaA, Thermo Fisher Scientific, Lonza, HiMedia Laboratories, Agilent Technologies, and PromoCell GmbH. Contamination of cell culture is the most prominent factor restricting the growth of cell culture consumables and equipment market. Contaminated culture is the presence of non-living substances or unwanted foreign microorganisms that have undesirable effects on the cell culture. Using contaminated culture cells has several negative consequences on the users and thus hampers the growth of this market. For example, an article published on MedCrave, stated that Mycoplasma is one of the most common and difficult to detect contaminants. The article also highlighted the results of a study on fibroblasts and keratinocyte cell lines that showed 32.35% of contamination, out of which 17.65% were mycoplasma contaminated cultures, followed by fungal (8.82%) and bacterial (5.88%) contaminants. Hence, the high risk associated with cell culture techniques poses a threat to the growth of the cell culture consumables and equipment market. Companies in cell culture consumables and equipment are investing more in 3D cell culture for its new and advantageous features. 3D cell culture may be defined as the culture of living cells within micro-assembled devices and supports that present a three-dimensional structure and are used to replicate a tissue or an organ in an artificial environment by allowing the cells to interact with the surroundings in all three directions. 3D cell cultures are more relevant with a higher degree of structural complexity and maintain the steady-state for more time as compared to 2D cell cultures. In August 2021, Amerigo Scientific, a US-based manufacturer of biomedical and life sciences products, launched #D cell cultures for research purposes. FDA regulates cell culture consumables and equipment in the U.S. Under title 21, Sec 864.2240. For cell and tissue culture equipment, the FDA states that if the equipment is not labelled or mentioned as sterile, it would be removed from the good manufacturing practises of the quality system. Additionally, each manufacturing unit should maintain procedures to receive, review, and evaluate complaints. These procedures require consistency and punctuality, along with the documentation of the receipts. Therefore, these regulatory standards improve the safety and efficacy of instruments and consumables used during cell culture processes. In July 2021, Sartorius, a Germany-based laboratory instrument manufacturer, acquired Xell AG for an undisclosed amount. The acquisition would expand Sartorius’ current media offering and other cell culture products. Xell AG is a Germany-based cell culture specialist. North America was the largest region in the cell culture consumables and equipment market in 2022. Western Europe was the second largest region in the global cell culture consumables and equipment market share. The regions covered in the global cell culture consumables and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cell culture consumables and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cell culture consumables and equipment market consists of sales of flasks, tubes, dishes or cryovials, serological pipettes or centrifugation tubes, bottles, cell scrapers, strainers, coverslips, and inserts. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The cell culture consumables and equipment market research report is one of a series of new reports from The Business Research Company that provides cell culture consumables and equipment market statistics, including cell culture consumables and equipment industry global market size, regional shares, competitors with a cell culture consumables and equipment market share, detailed cell culture consumables and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cell culture consumables and equipment industry. This cell culture consumables and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Transplant diagnostics are the tests conducted before relocation/ transplantation of the donor organ to the recipient patient. Histocompatibility and immunogenetics are the main topics of transplantation diagnostics in the context of organ transplantation and hematopoietic stem cell transplantation. The main types of transplant diagnostics market are reagents and consumables, instruments, and software and services. The transplant diagnostics instruments are products that are designed to speed up and improve the quality of transplant diagnostics. The technologies used in transplant diagnostics are non-molecular assay, and molecular assay to transplant various organs such as kidney, liver, heart, lung, and pancreas. The transplant types included are solid organ and stem cells that are used by end-users such as hospitals and transplant centres, research laboratories and transplant centres, and commercial service providers. The global transplant diagnostics market is segmented - 1) By Type: Reagent & Consumables, Instrument, Software & Services 2) By Transplant Type: Solid Organ, Stem Cell 3) By End User: Hospitals and Transplant Centers, Research Laboratories & Transplant Centers, Commercial Service Providers 4) By Technology: Non Molecular Assay, Molecular Assay 5) By Organ: Kidney, Liver, Heart, Lung, Pancreas The global transplant diagnostics market size grew from $1.66 billion in 2022 to $1.82 billion in 2023 at a compound annual growth rate (CAGR) of 9.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global transplant diagnostics is expected to grow from $2.4 billion in 2027 at a CAGR of 7.2%. Rising incidents of acute diseases are leading to an increase in organ failure rates, thus increasing the demand for transplant procedures driving the transplant diagnostics market. Organ transplant is a complex process and the success of the procedure depends on the acceptance of the donor's organ by the recipient's body system. To check whether the organ transplant can be successful, transplant diagnostic tests are performed. According to the United Network for Organ Sharing, a US-based non-private organization that manages organ transplantation in the US, in the year 2021, The U.S. saw a record-setting number of organ transplants. 24,669 kidney transplants, 9,236 liver transplants, and 3,817 heart transplantation procedures were performed in 2021. This high demand for diagnostic tests is driving the transplant diagnostics market. Major players in the transplant diagnostics market are Thermo Fisher ScientificInc., Illumina Inc., F. Hoffmann La-Roche AG., Abbott Laboratories Inc., Qiagen N.V., Immucor Transplant Diagnostics Inc., Bio-rad Laboratories Inc., Omixon Ltd., CareDx, Affymetrix Inc., and GenDx. A huge gap between organ donation and demand for organ transplantation is restraining the growth of the transplant diagnostics market. The number of organ donors is increasingly falling short of the number of people requiring organ transplantation. According to Health Resources and Services Administration in 2021, 106,090 people were on the waiting list for receiving organ donation. This is creating a huge deficit between the supply and demand of organ donors, with the number of people on the waiting list for organ transplants growing increasing with each passing year. This low number of organ donors is limiting the need for transplant diagnostic tests and devices, thus restraining the market growth. Companies in the transplant diagnostics market are using Next Generation Sequencing (NGS) for conducting tests to match organ donors and recipients. NGS technology allows the sequencing of an entire human genome, i.e. millions of DNA molecules within a single day. In Next-generation sequencing (NSG), genes are matched between the donor and recipient and depending on the extent of the match, a decision to perform organ transplantation is made. Nearly all transplant diagnostic tests and devices currently use this technology to decide on organ transplantation. For example, Castle Biosciences launched the Decision Dx-CMSeq Test that used NGS (Next Generation Sequencing) to identify somatic mutations in genes. The transplant diagnostics market is regulated by authorities such as the US Food and Drug Administration (FDA). For instance, companies in the transplant diagnostics market must comply with the Good Laboratories Practices (GLP) Part 58 directed by the FDA Title 21. According to this regulation, all the clinical instruments used to diagnose specimens must be maintained under specified conditions and should be properly calibrated, so that there should be minimal distortion in the result. The testing facility must be equipped with a quality assurance unit to monitor each piece of equipment, personnel, methods, practices, record, and controls. In August 2022, Eurobio Scientific, a France-based biotechnology company, acquired GenDx for $134.3 million(€135 million). The acquisition would help Eurobio to expand its research in the areas of transplantation. Genome Dx is a Netherlands-based molecular diagnostics startup. North America was the largest region in the transplant diagnostics market in 2022. Western Europe was the second largest region in the transplant diagnostics market report. The regions covered in the transplant diagnostics industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the transplant diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The transplant diagnostics market includes revenues earned by entities by PCR-based molecular assays, sequencing-based molecular assays, and non-molecular assay technologies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The transplant diagnostics market research report is one of a series of new reports from The Business Research Company that provides transplant diagnostics market statistics, including transplant diagnostics industry global market size, regional shares, competitors with a transplant diagnostics market share, detailed transplant diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the transplant diagnostics industry. This transplant diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Flow cytometry is a technique in which cells are added to a fluid medium, which is then passed through a pulsating laser beam. The cell then scatters the beam in different directions towards receptors that capture the light and translate it into data displayed on a monitor. Flow cytometry is used to analyze characteristics of a biological cell, such as cell size, cell count, and cell complexity, using laser optics. The main types of flow cytometry are instruments, reagents and consumables, software, accessories, and services. Flow cytometry services include experimental design, specimen processing, acquisition, and data analysis to support researchers, biotech companies, and pharmaceutical companies in the process of drug development. The various technologies involved are cell-based and bead-based and are used in oncology, drug discovery, disease diagnosis, stem cell therapy, organ transplantation, and hematology. The different end-users include hospitals and clinics, academia and research institutes, pharmaceutical and biotechnology companies, and other end users. The global flow cytometry market is segmented - 1) By Type: Instruments, Reagents & Consumables, Software, Accessories, Services 2) By Technology: Cell-Based, Bead-Based 3) By End User: Hospitals And Clinics, Academia And Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users 4) By Application: Oncology, Drug Discovery, Disease Diagnosis, Stem Cell Therapy, Organ Transplantation, Hematology The global flow cytometry market size will grow from $5.72 billion in 2022 to $6.25 billion in 2023 at a compound annual growth rate (CAGR) of 9.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global flow cytometry is expected to grow to $9.04 billion in 2027 at a CAGR of 9.7%. The increasing number of HIV cases globally is an important driver for the flow cytometry market. This is because the flow cytometry technique has its direct application in HIV diagnosis. Flow cytometry uses light scattering to determine the identity of cells. These cells are given certain markers called CDs (clusters of differentiation), based on the type of scattering. For the HIV virus cell, the clusters of differentiation is called CD4, and based on the number of CD4s in a medium, flow cytometry can be used to diagnose HIV. As the global HIV population continues to grow, the demand for diagnosis techniques such as flow cytometry is also increasing. Major players in the flow cytometry market are Beckman Coulter, Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher, Luminex, Miltenyi Biotec, Becton Dickinson and Company, Sysmex, Merck KGAA, Danaher Corporation, Apogee, Stratedigm, General Electric Company, EMD Millipore, Affymetrix, Biomérieux S.A., Cytonome St, Enzo Life Sciences, Enzo Biochem, Sony Biotechnology, Sysmex Partec, Life Technologies, BD, ACEA BIO, and TAKARA BIO. The availability of cheaper and better substitutes for flow cytometry is a major restrain on the flow cytometry market. These substitutes include ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay. While flow cytometry, ELISA and radioimmunoassay are all methods that help in HIV diagnosis by detecting “problem cells” in a group of cells, ELISA and radioimmunoassay are cheaper and easier methods than flow cytometry. In ELISA, colour changes in reagents are used to detect problematic cells. While in radioimmunoassay, cells are given certain radioactive markers which are used to detect problematic cells. Both ELISA and radioimmunoassay can be implemented using cheap, traditional laboratory equipment and reagents with a higher throughput rate. However, flow cytometry involves high setup costs and costs of interpreting data along with a very low throughput. High-throughput flow cytometry is an emerging trend in the flow cytometry market. This is due to high speed of cell parameter processing and capability to analyze several heterogeneous cell groups at once, using this technique. Traditional cytometry methods are very slow, especially when several cells need to be tested within a day. Using high-throughput flow cytometry methods such as fluorescence-activated cell-sorting (FACS), multiple cells can be allotted fluorescent markers which can be used to analyze their parameters in quick time. Examples of companies that offer high-throughput flow cytometry solutions include AstraZeneca and Novartis. The US FDA's code of federal regulations (CFR) includes regulations related to a flow cytometry device called the automated differential cell counter (ADCC). An ADCC is a device used in the study of blood cells, mainly for the detection of faulty blood cells and low blood cell counts. This device comes under the purview of the class 2 special controls guidance document which outlines requirements such as the methods for accurate and precise reporting of results, the statistical linearity conditions of graph-based cytometry results and the types of specimens to be used. Flow cytometry device manufacturers must conform to these guidelines, which address the specific health risks associated with ADCC devices. Hence, this is expected to maintain a vigil on flow cytometry companies involved in manufacturing ADCC. In February 2022, KCAS Bioanalytical and Biomarker Services, a US-based GLP and GCP-compliant development service provider, acquired FlowMetric LLc for an undisclosed amount. The acquisition would help KCAS build strong foundations in the field of analytical testing. FlowMetric is a US-based provider of flow cytometry and cellular assay services. North America was the largest region in the flow cytometry market in 2022. Western Europe was the second largest region in the global flow cytometry market analysis. The regions covered in the global flow cytometry market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the flow cytometry market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The flow cytometry market includes revenue earned by cytometry systems, panel builders, and instruments. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The flow cytometry market research report is one of a series of new reports from The Business Research Company that provides flow cytometry market statistics, including flow cytometry industry global market size, regional shares, competitors with a flow cytometry market share, detailed flow cytometry market segments, market trends and opportunities, and any further data you may need to thrive in the flow cytometry industry. This flow cytometry market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Stem cell/cord blood banking is the process of storing stem cells or blood from the umbilical cord. It is used to treat future injuries. By taking stem cells from the placenta and umbilical cord and preserving them for later use, cord blood banking can possibly save lives. The main cell types of stem cell/cord blood banking are adult stem cells, umbilical cord blood stem cells, and embryonic stem cells. Adult stem cells are a rare population of cells found in the body for the majority of postnatal life that give rise to a limited number of mature cell types that form the tissue in which they dwell. The different types of services include collection, processing, analysis, storage and involves various types of banks such as private banks, and public banks. The different applications include leukemia, anemia, thalassemia, autism, cerebral palsy, diabetes, and others. The global stem cell/cord blood banking market is segmented - 1) By Cell Type: Adult Stem Cells, Umbilical Cord Blood Stem Cells, Embryonic Stem Cells 2) By Service: Collection, Processing, Analysis, Storage 3) By Bank Type: Public, Private 4) By Application: Leukemia, Anemia, Thalassemia, Autism, Cerebral Palsy, Diabetes, Other Applications The global stem cell/cord blood banking market size will grow from $10.23 billion in 2022 to $11.15 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global stem cell/cord blood banking is expected to grow to $16.36 billion in 2027 at a CAGR of 10.1%. Increasing number of cancer patients is a major driver for the stem cell /cord blood banking market. Cancer diseases such as leukemia and multiple myeloma can be treated by stem cell transplant. In stem cell transplant, treatment can be either done by autologous transplant in which the stem cells come from the same person who gets the transplant or by allogeneic transplant in which means the stem cells come from a matched related or unrelated donor. By using stem cells in the treatment of cancer, the blood forming stem cells which are damaged during chemotherapy can be restored. According to a report by WebMD,an American publisher of health related news, in 2021, 10 million people died of cancer worldwide. which can be treated by transplanting the stem cells. Major players in the stem cell/cord blood banking market are AMAG Pharmaceuticals, Cordlife, Cryo-Cell International, Esperite, Americord Registry LLC., China Cord Blood Corporation, Cordlife Group Limited, CordVida, ESPERITE N.V., and Cryo Stemcell. Lack of awareness especially among pregnant women is a major restraint for the stem cell/cord blood banking market. This is mainly because a majority of pregnant women are unaware of the functioning of the public cord blood banks. Hence, this option is not fully explored despite the advantages of stem cell transplantation in treating cancer. For example, according to the survey by International Journal of Reproduction, Contraception, Obstetrics and Gynecology (IJRCOG), only 45% of pregnant women were informed about the uses of umbilical cord blood during pregnancy, just 5% were aware about the cost of the procedure and less than 1% were aware about the availability of cord blood banking market. Pairing of cord blood and tissue storage with genetic testing services is an emerging trend in the stem cell/cord blood banking market. Such pairing is possible and efficient because of its complimentary services to the existing clients, thereby helping in expanding their product portfolio. For example, genetic testing company Natera launched the Evercord cord blood and tissue storage service that enables expectant parents to collect, store and potentially retrieve their newborn's cord blood and tissue for therapeutic use in transplantation and regenerative medicine applications. The US Food and Drug Administration (FDA) outlines guidance related to stem cells/cord blood banking in accordance with section 212 of the Small Business Regulatory Enforcement Fairness Act (Public Law 104-121). As per this act, stem cells sourced from cord blood for unrelated allogeneic use are regulated by the FDA, and, in order to distribute these products, distributors need to get a license from the FDA. These licenses are provided by the FDA after reviewing the manufacturing and the storage conditions. In this regard, the American Association of Blood Banks (AABB) and other regulatory agencies also work with the FDA. Hence, the regulatory scenario related to the stem cells/cord blood banking market is expected to keep a check on companies involved in this market. In December 2021, Cooper Companies, a U.S.-based medical device company, acquired Generate Life Sciences for $1.66 billion. The acquisition would enable Cooper & Co. to better serve their consumers and expand their customer base. Generate Life Sciences is a US-based provider of donor eggs and sperm for fertility treatments, fertility cryopreservation services, and newborn stem cell storage (cord blood and cord tissue) services. North America was the largest region in the stem cell/cord blood banking market in 2022. Western Europe was the second largest region in the global stem cell/cord blood banking market analysis. The regions covered in the global stem cell/cord blood banking market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the stem cell/cord blood banking market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The stem cell/cord blood banking global market includes revenues earned by entities by providing services such as cryopreservation and collection services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The stem cell/cord blood banking market research report is one of a series of new reports from The Business Research Company that provides stem cell/cord blood banking market statistics, including stem cell/cord blood banking industry global market size, regional shares, competitors with a stem cell/cord blood banking market share, detailed stem cell/cord blood banking market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell/cord blood banking industry. This stem cell/cord blood banking market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Induced pluripotent stem cells are the regenerated form of stem cells, which are produced from an existing adult cell, such as from hepatocytes, fibroblasts, keratinocytes, and neurons. The main derived cell types of induced pluripotent cells are hepatocytes, fibroblasts, keratinocytes, amniotic cells, and others. Hepatocytes are the liver's primary functional cells, performing a staggering array of metabolic, endocrine, and secretory tasks. The various application includes academic research, drug development, and discovery, toxicity screening, and regenerative medicine and are used in several sectors such as hospitals, and research laboratories. The global induced pluripotent stem cell (iPSC) market is segmented - 1) By Derived Cell Type: Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Other Derived Cells 2) By Application: Academic Research, Drug Development And Discovery, Toxicity Screening, Regenerative Medicine 3) By End-User: Hospitals, Research Laboratories The global induced pluripotent stem cell (ipsc) market size will grow from $2.69 billion in 2022 to $2.97 billion in 2023 at a compound annual growth rate (CAGR) of 10.5% . The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global induced pluripotent stem cell (ipsc) market is expected to grow to $4.36 billion in 2027 at a CAGR of 10.1% . An increase in the prevalence of chronic disorders is one of the major factors that is driving the growth of the Induced pluripotent stem cell market. Chronic disorders like heart disease, cancer, stroke, diabetes can be treated with Induced pluripotent stem cell. Induced Pluripotent stem cells are taken from any tissues from a child or an adult and are genetically modified to behave like embryonic stem cells. According to the report published by Partnership to Fight Chronic Disorder (PFCD), it was found that out of 133 million Americans, 45% of the population had at least one chronic disorder. Moreover, it was estimated that 7 out of 10 deaths in the USA, which is approximately 1.7 million, are due to chronic disorders and these deaths can be controlled by induced pluripotent stem cell treatment. This rise in incidences of chronic diseases is driving the demand for induced pluripotent stem cell treatment market. Major players in the induced pluripotent stem cell (iPSC) market are Thermo Fisher Scientific Inc., FUJIFILM Holdings Corporation (Cellular Dynamics), Takara Bio Inc., Astellas Pharma Inc., Fate Therapeutics, ViaCyte, StemCells, Japan Tissue Engineering Co. Ltd., Fate Therapeutics and Japan Tissue Engineering Co . The potential risk of tumour is one of the major restraints on the growth of the Induced pluripotent stem cell market. As per a scientific research, it was found that there might be a chance of getting cancer from the treatment and people are unwilling to take treatment through Induced pluripotent stem cell therapy. According to the report by American Association for cancer research, in most of the cases while doing the experiment it was found that the occurrence of the tumours was prevalent after a short period of time. This risk of developing a tumour due to Induced pluripotent stem cell therapy is limiting the number of patients opting for this treatment, thereby restraining the growth of the market. Companies in the Induced Pluripotent stem cell market are looking for opportunities for strategic partnerships and collaborations that will help these companies to enter into new geographies and to expand product portfolios. For example, in January 2022, Bristol Myers Squibb and Century Therapeutics entered into a strategic collaboration to develop iPSC-derived allogenic cell therapies for the treatment of acute myeloid leukemia and multiple myeloma. Furthermore, in May 2022, Evotec and Sernova announced strategic partnership to develop iPSC-based beta cell replacement therapy for treatment for type 1 and type 2 diabetes. National Institute of Health (NIH), a part of Department of Health and Human Services, regulates the market for Induced Pluripotent stem cells (iPSC) in the US. If a company is using, making or planning to acquire iPSCs, they are required to provide some information. For instance, a complete and signed copy of the IPSC checklist must be submitted. Any acquisitions in the IPSC’s must obtain approval from the Institutional review board (IRB), the signed approval documents must be attached to the checklist. If the IPSC lines are purchased from an outside or commercial source these agreement documents must also be attested by the IRB and attached. The IPSC’s must be generated by the Intramural Research Program (IRP) under a signed contract before they can be used for any further experimentation. In August 2021, catalant, a Us-based pharmaceutical company, acquired RheinCell Therapeutics GmbHfor an undisclosed amount. The acquisition will help Catalent to grow in the cell and gene therapy vertical and develop therapies based on induced pluripotent stem cells. RheinCell Therapeutics GmbH is a Germany-based developer of human induced pluripotent stem cells (iPSCs) for next generation cell therapies. North America was the largest region in the induced pluripotent stem cell (iPSC) market in 2022. Western Europe was the second largest region in the global induced pluripotent stem cell (iPSC) market share. The regions covered in the global induced pluripotent stem cell (iPSC) market report analysis are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the induced pluripotent stem cell (iPSC) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The induced pluripotent stem cell (iPSC) market consists of sales of induced pluripotent stem cells and related services. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The induced pluripotent stem cell (iPSC) market research report is one of a series of new reports from The Business Research Company that provides induced pluripotent stem cell (iPSC) market statistics, including induced pluripotent stem cell (iPSC) industry global market size, regional shares, competitors with an induced pluripotent stem cell (iPSC) market share, detailed induced pluripotent stem cell (iPSC) market segments, market trends and opportunities, and any further data you may need to thrive in the induced pluripotent stem cell (iPSC) industry. This induced pluripotent stem cell (iPSC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Stem cells are autologous or allogenic cells that can differentiate into various types of cells in vivo and in vitro.They aid in medical treatment of injuries and organ damage. The main product types of stem cell are adult stem cell, human embryonic stem cell, induced pluripotent stem cell and others. Adult stem cells are a rare population of cells found in the body for the majority of postnatal life that give rise to a limited number of mature cell types that form the tissue in which they dwell. The different sources include autologous, allogeneic and are used in various applications such as regenerative medicine, drug discovery, and development. The global stem cell market is segmented - 1) By Source: Autologous, Allogeneic 2) By Product Type: Adult Stem Cell, Human Embryonic Stem Cell, Induced Pluripotent Stem Cell, Other Products 3) By Application: Regenerative Medicine, Drug Discovery And Development The global stem cell market grew from $12.72 billion in 2022 to $13.97 billion in 2023 at a compound annual growth rate (CAGR) of 9.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The stem cell market is expected to grow from $20.67 billion in 2027 at a CAGR of 10.3%. There is an increase in the prevalence of Chronic diseases worldwide which drives the Stem cell market. Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use. Currently, widely used stem cell treatment is the transplantation of blood stem cells to treat diseases and conditions of the blood and immune system, or to restore the blood system after treatments for specific cancers. According to WHO, in 2020, prevalence of chronic disease increased to 57%. As the prevalence of chronic disease increases, people opting for the stem cell-based treatment will rise, thus driving the market going forward. Currently, approximately 26,000 patients are treated with blood stem cells in Europe each year. Major players in the stem cell market are Anterogen Co., Ltd., Mesoblast Ltd., Osiris TherapeuticsInc., AlloSource, Cellular Engineering Technologies, BIOTIMEInc., Astellas Pharma USInc., Vericel, RTI SurgicalInc. and Takara Bio Company. The low acceptance rate for stem cell therapy treatments is restraining the growth of the stem cell market. The acceptance rate is particularly low in the Embryonic stem cell therapeutics. Most of these stem cell therapies are yet to be proven in clinical trials and are highly experimental. Due to the nature of these unproven treatments, patients are reluctant to take up these therapies as they present serious health, personal and financial issues. For example, if a person undergoes an unproven or experimental treatment it might make that person ineligible for future clinical trials or treatment options. For instance, in USA, an unproven stem cell offering three elderly women were blinded after getting stem cells derived from fat tissue, at a clinic in Florida These factors are limiting the number of people opting for stem cell therapies, thus restraining the growth of the stem cell market. Companies in the stem cell therapeutics market are focusing on development of new technologies such as the Induced Pluripotent Stem Cells (IPSC) to boost the efficiency of stem cell therapies. IPSC are obtained from blood or skin cells that are reprogrammed to an embryonic-like pluripotent state by incorporating genes that are essential for maintaining key properties and growth of an unlimited source of any kind of human cell required for stem cell therapeutic purposes. These IPSC's are not derived from human embryos, which removes the bioethical issues, thus allowing scientists to obtain federal funding and support easily. A Japanese company, Oksara opened a medicine center that produced cells derived from iPS Cells. Similarly, Takar Bio company launched human iPSC derived Beta Cells i.e., Cellartis for disease modeling and drug discovery. The Food and Drug Administration's Centre for Biologics Evaluation and Research (CBER) is the regulator in the US, for human cells, tissues, and cellular and tissue-based products (HCT/P) intended for implantation, transplantation, infusion or transfer into a human recipient, including hematopoietic stem cells. There are certain protocols that the FDA has established, for example, the current good tissue practice, donor screening and donor testing requirements which are in place to prevent the transmission of any communicable diseases. The stem cells come from different sources (bone marrow, umbilical cord blood or peripheral blood) and have different applications. Licenses are required to distribute and market these products. In August 2021, Catalent, a US-based provider of advanced delivery technologies, development, and manufacturing solutions for pharmaceuticals, biologics, and cell and gene treatments acquired RheinCell Therapeutics GmbH for an undisclosed amount. With this acquisition Catalent aims to deploy RheinCell's expertise and deep knowledge in iPSC cell lines that will boost Catalent’s cell therapy portfolio, allowing them to offer iPSC banks to their customers as a premium source for their therapeutic development pathway. RheinCell Therapeutics GmbH is a Germany based company that specializes in the GMP-compliant generation of human induced pluripotent stem cells (iPS cells). North America was the largest region in the stem cell market in 2022. Western Europe was the second largest region in the global stem cell market share. The regions covered in the global stem cell market market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the stem cell market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The stem cell market consists of sales of organoids & 3D Cell Culture, mesenchymal Stem Cells, neural stem cells, hematopoietic stem cells, and cancer stem cells. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The stem cell market market research report is one of a series of new reports from The Business Research Company that provides stem cell market market statistics, including stem cell market industry global market size, regional shares, competitors with a stem cell market market share, detailed stem cell market market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell market industry. This stem cell market market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell therapy refers to the replacement or repair of damaged tissue and/or cells through the transplantation of human cells. Numerous different types of cells may be used as part of a therapy or treatment for a number of diseases and disorders with the help of new technologies, inventive products, and infinite imagination. It is a form of treatment wherein a patient receives live cells via injection, grafting, or implant in order to produce a therapeutic result. The main techniques used in cell therapy are stem cell therapy, cell vaccines, adoptive cell transfer (ACT), fibroblast cell therapy, and chondrocyte cell therapy. Stem cell treatment, also known as regenerative medicine, uses stem cells or their derivatives to stimulate the healing response of sick, defective, or wounded tissue. The different types of therapies include allogeneic therapies, and autologous therapies and are used in various applications such as oncology, cardiovascular disease (CVD), orthopaedics, wound healing, and others. The global cell therapy market is segmented - 1) By Technique: Stem Cell Therapy, Cell Vaccine, Adoptive Cell Transfer (ACT), Fibroblast Cell Therapy, Chondrocyte Cell Therapy 2) By Therapy Type: Allogeneic Therapies, Autologous Therapies 3) By Application: Oncology, Cardiovascular Disease (CVD), Orthopedic, Wound Healing, Other Applications The global cell therapy market size grew from $10.74 billion in 2022 to $12.8 billion in 2023 at a compound annual growth rate (CAGR) of 19.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of the global cell therapy market is expected to grow from $22.33 billion in 2027 at a CAGR of 14.9%. The rising prevalence of chronic diseases aided the expansion of the cell therapy market. According to the US Centers for Disease Control and Prevention (CDC), chronic disease is a condition that lasts for one year or more, requires medical attention, limits daily activities, or both, and includes heart disease, cancer, diabetes, and Parkinson’s disease. Stem cells can benefit patients suffering from spinal cord injuries, type 1 diabetes, Parkinson’s disease (PD), heart disease, cancer, and osteoarthritis. For instance, according to the Center for Disease Control and Prevention report in 2021, due to poor nutrition and a lack of physical activity, 6 in 10 adults in the USA are suffering from a chronic disease, and 4 in 10 have two or more diseases. In December 2021, according to the International Diabetes Federation, a Belgium based health organization, about 537 million people (20–79 years old) will have diabetes. By 2030, there will be 643 million diabetics worldwide, and by 2045, there will be 783 million. Nearly one-half of all diabetics (240 million) go undiagnosed, and three out of every four diabetic adults live in low- and middle-income countries. According to the Parkinson’s Foundation, in 2021, approximately 60,000 Americans will be diagnosed with PD each year, and 10 million individuals worldwide will suffer from this disease. After Alzheimer's, it is the second most prevalent neurological disease. The growing prevalence of chronic diseases increased the demand for cell therapies and contributed to the growth of the cell therapy market. Major players in the cell therapy market report are Fibrocell Science Inc., JCR Pharmaceuticals Co. Ltd., PHARMICELL Co. Ltd., Osiris Therapeutics Inc., MEDIPOST, Vericel Corporation, Anterogen Co. Ltd., KolonTissueGene Inc., Stemedica Cell Technologies Inc. and AlloCure. The high cost of cell therapy has hindered the growth of the cell therapy industry. Cell therapies have become a common choice of treatment in recent years as people look for the newest treatment options. Although there is a huge increase in demand for cell therapies, they are still very costly to try. Basic joint injections can cost around $1,000, and more specialised procedures can cost up to $100,000 depending on the condition.In the United States, the average cost of stem cell therapy in 2020 is expected to range between $4,000 and $8,000 per patient. Therefore, the high cost of cell therapy restrains the growth of the cell therapy market. Key market players are strategically partnering and collaborating to expand the company's product portfolio and geographical presence. For instance, in October 2021, Takeda, a Japan-based pharmaceutical company, acquired GammaDelta Therapeutics, a US-based company that offers cell therapies, to speed up the development of allogeneic T cell therapies for solid tumours. Furthermore, in November 2020, Sanofi, a US-based pharmaceutical company, acquired Kiadis, a Netherlands-based pharmaceutical company, to boost cell therapy, which is used to develop treatments for life-threatening diseases. Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company specialising in drug development and commercialization, paid $100 million for GammaDelta Therapeutics Limited in October 2021. Through this acquisition, Takeda will acquire early-stage cell therapy programmes in addition to GammaDelta's allogeneic variable delta 1 (V1) gamma-delta T cell therapy platforms, which encompass both blood-derived and tissue-derived platforms. GammaDelta Therapeutics Limited is a UK-based biotechnology company specialising in the research and development of T-cell therapy and immunotherapy for cancer treatment. North America was the largest region in the cell therapy market in 2022. The regions covered in the cell therapy market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cell therapy market includes revenues earned by entities by enhancing the growth of new healthy skin tissue and enhancing collagen production. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified), or as part of other products. The cell therapy market research report is one of a series of new reports from The Business Research Company that provides cell therapy market statistics, including cell therapy industry global market size, regional shares, competitors with a cell therapy market share, detailed cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy industry. This cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.